However, at multivariate analysis, including the achievement of the mitotane target levels and the time to progression pre-mitotane treatment (preM-TTP), considered as the time from ACC diagnosis to first radiological evidence of recurrence or progression, the CYP2W1*6 SNP was not more significant (HR = 1.54, 95% CI 0.91–2.61, p = 0.10; Table 4). Here, CYP2W1 is linked to adrenal cortex carcinoma.